Apple Continues to Be the World's Most Admired Company
Apple has been ranked as Fortune's Most Admired Company for the 18th consecutive year. The Fortune rankings are based on a survey of ...
Apple named Fortune’s Most Admired Company for 18th year running
For the 18th year running, Apple has been named Fortune’s Most Admired Company. The rankings are based of a survey of more than 3,000 company execs across 30 countries. While Apple’s number one ...
Levi & Korsinsky Notifies Shareholders of Novo Nordisk A/S (NVO) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / January 29, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
JPMorgan raises Ascendis Pharma target to $167, keeps Overweight
JPMorgan analyst Jessica Fye adjusted the price target for Ascendis Pharma (NASDAQ:ASND), a $7.74 billion biotech company, to $167.00, a slight increase from the previous $165.00, while reiterating ...
Jim Cramer Says Novo Nordisk A/S (NVO) Is ‘Down So Much’
We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we ...
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding its use
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
Pharma is hopeful about Trump's second term — here's what to expect for drugmakers
Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
American Express CFO says spending picked up at year-end, thanks to millennials and Gen Z
The pickup was especially fueled by millennials and Gen Z users, who spent more on experiences such as travel and entertainment.
Foreigners are chasing U.S. stocks. Historically, that's a bad sign.
If there's a group even dumber, unfortunately, it would be foreign retail investors. And they're buying U.S. stocks like they're going out of fashion.
J.P. Morgan Keeps Their Buy Rating on Novo Nordisk (0QIU)
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...
STAT6d
Novo Nordisk’s next-generation obesity treatment shows promise in early study
A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...